drugset / Trial / NCT06026800
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
Phase 1
Recruiting
20 enrolled
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 in combination with first-line treatment in subjects with advanced digestive system neoplasms.
Timeline
- Start
- 2023-09-08
- Primary completion
- 2027-08-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iNeo-Vac-R01 | Messenger RNA (mRNA) | — | Other |